Scarica l'app Stockscreener
19.61
0.36%
0.07
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché APLS Giù?
Forum
Previsione
Precedente Chiudi:
$19.54
Aprire:
$19.45
Volume 24 ore:
1.45M
Relative Volume:
0.58
Capitalizzazione di mercato:
$2.48B
Reddito:
$715.22M
Utile/perdita netta:
$-250.10M
Rapporto P/E:
-9.6601
EPS:
-2.03
Flusso di cassa netto:
$-205.58M
1 W Prestazione:
-3.54%
1M Prestazione:
-30.73%
6M Prestazione:
+12.57%
1 anno Prestazione:
-29.33%
Intervallo 1D:
$19.40
$19.95
Intervallo di 1 settimana:
$19.31
$20.57
Portata 52W:
$16.10
$35.72
Apellis Pharmaceuticals Inc Stock (APLS) Company Profile
Nome
Apellis Pharmaceuticals Inc
Settore
Industria
Telefono
617-977-5700
Indirizzo
100 FIFTH AVENUE, WALTHAM, KY
Confronta APLS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
APLS
Apellis Pharmaceuticals Inc
|
19.61 | 2.47B | 715.22M | -250.10M | -205.58M | -2.03 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-06 | Iniziato | Wolfe Research | Peer Perform |
| 2025-10-15 | Iniziato | Wells Fargo | Overweight |
| 2025-09-26 | Downgrade | Goldman | Neutral → Sell |
| 2025-05-09 | Downgrade | BofA Securities | Buy → Neutral |
| 2025-05-09 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2025-04-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-17 | Downgrade | Goldman | Buy → Neutral |
| 2024-11-21 | Iniziato | Morgan Stanley | Equal-Weight |
| 2024-10-25 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-10-16 | Iniziato | William Blair | Outperform |
| 2024-05-31 | Iniziato | Piper Sandler | Neutral |
| 2024-02-05 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-12-14 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-11-09 | Iniziato | Goldman | Buy |
| 2023-11-02 | Iniziato | Mizuho | Neutral |
| 2023-10-06 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-09-15 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-08-29 | Reiterato | Citigroup | Buy |
| 2023-08-03 | Downgrade | JP Morgan | Overweight → Neutral |
| 2023-08-01 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-01-03 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-11-10 | Downgrade | Jefferies | Buy → Hold |
| 2022-07-19 | Iniziato | H.C. Wainwright | Buy |
| 2022-06-17 | Ripresa | Stifel | Buy |
| 2022-04-14 | Downgrade | ROTH Capital | Neutral → Sell |
| 2021-12-08 | Iniziato | Wells Fargo | Overweight |
| 2021-11-29 | Downgrade | ROTH Capital | Buy → Neutral |
| 2021-09-10 | Reiterato | BMO Capital Markets | Outperform |
| 2021-09-10 | Reiterato | Credit Suisse | Neutral |
| 2021-09-10 | Reiterato | Needham | Buy |
| 2021-09-10 | Reiterato | Oppenheimer | Outperform |
| 2021-09-10 | Downgrade | Wedbush | Outperform → Neutral |
| 2021-08-19 | Iniziato | Jefferies | Buy |
| 2021-08-19 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-04-16 | Iniziato | Goldman | Buy |
| 2020-11-19 | Iniziato | Needham | Buy |
| 2020-09-01 | Iniziato | Stifel | Buy |
| 2020-07-20 | Iniziato | ROTH Capital | Buy |
| 2020-06-17 | Iniziato | BTIG Research | Neutral |
| 2020-04-01 | Iniziato | Raymond James | Strong Buy |
| 2020-03-31 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-11 | Aggiornamento | Wedbush | Underperform → Neutral |
| 2020-01-07 | Iniziato | SVB Leerink | Mkt Perform |
| 2019-12-19 | Iniziato | BofA/Merrill | Buy |
| 2019-11-22 | Iniziato | Wedbush | Underperform |
| 2019-11-05 | Iniziato | Credit Suisse | Neutral |
| 2019-08-01 | Reiterato | Cantor Fitzgerald | Overweight |
| 2019-07-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-03-29 | Iniziato | Robert W. Baird | Outperform |
| 2019-01-23 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-07-30 | Aggiornamento | B. Riley FBR | Neutral → Buy |
| 2018-05-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-04-12 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-02-08 | Iniziato | B. Riley FBR, Inc. | Buy |
Mostra tutto
Apellis Pharmaceuticals Inc Borsa (APLS) Ultime notizie
Can Apellis Pharmaceuticals Inc. stock beat analyst upgradesShare Buyback & AI Powered Market Entry Ideas - newser.com
Will Apellis Pharmaceuticals Inc. stock deliver better than expected guidanceQuarterly Growth Report & Daily Oversold Stock Bounce Ideas - newser.com
Does Apellis Pharmaceuticals Inc. (1JK) stock trade below intrinsic valueQuarterly Investment Review & Safe Entry Momentum Tips - newser.com
Apellis Pharmaceuticals Faces Weak Start with 17.3% Gap Down Amid Market Concerns - Markets Mojo
Why Apellis Pharmaceuticals Inc. (1JK) stock stays on buy listsShare Buyback & Safe Swing Trade Setups - newser.com
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Looks Inexpensive After Falling 28% But Perhaps Not Attractive Enough - 富途牛牛
Using AI based signals to follow Apellis Pharmaceuticals Inc.Gold Moves & Free Safe Entry Trade Signal Reports - newser.com
Apellis Pharmaceuticals Inc. stock prediction for this weekPortfolio Value Report & Stepwise Trade Execution Plans - newser.com
Risk vs reward if holding onto Apellis Pharmaceuticals Inc.2025 Price Action Summary & Real-Time Price Movement Reports - newser.com
Can Apellis Pharmaceuticals Inc. stock sustain market leadershipIndex Update & Weekly High Momentum Picks - newser.com
Can Apellis Pharmaceuticals Inc. stock resist sector downturnsTrade Exit Summary & Real-Time Buy Zone Alerts - newser.com
Will a bounce in Apellis Pharmaceuticals Inc. offer an exit2025 Bull vs Bear & Reliable Price Breakout Signals - newser.com
Why Apellis Pharmaceuticals Inc. stock is rated strong buyTrade Performance Summary & AI Powered Buy/Sell Recommendations - newser.com
Will Apellis Pharmaceuticals Inc. see short term momentum2025 Market Overview & AI Forecast for Swing Trade Picks - newser.com
Apellis Pharma general counsel Watson sells $100k in stock By Investing.com - Investing.com Canada
Apellis Pharma general counsel Watson sells $100k in stock - Investing.com
Apellis Pharmaceuticals General Counsel Sells 5,000 Shares - TradingView
[Form 4] Apellis Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Why Apellis Pharmaceuticals Inc. (1JK) stock could rally strongly2025 Bull vs Bear & Smart Money Movement Alerts - newser.com
Officer Watson Files To Sell 5,000 Of Apellis Pharmaceuticals Inc [APLS] - TradingView
Apellis Pharmaceuticals (BIT:1APLS) Price Target Decreased by 10.35% to 30.35 - Nasdaq
How Apellis Pharmaceuticals Inc. stock performs in weak economy2025 Growth vs Value & Fast Exit and Entry Strategy Plans - newser.com
What high frequency data says about Apellis Pharmaceuticals Inc.2025 Earnings Impact & Weekly High Momentum Picks - newser.com
Will breakout in Apellis Pharmaceuticals Inc. lead to full recovery2025 Short Interest & Real-Time Volume Triggers - newser.com
(APLS) Volatility Zones as Tactical Triggers - news.stocktradersdaily.com
How to build a dashboard for Apellis Pharmaceuticals Inc. stockVolume Spike & Free Daily Entry Point Trade Alerts - newser.com
Apellis Pharmaceuticals Inc Azioni (APLS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.38%
1.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):